The company informed the bourses that it allocated 66,65,725 equity shares at Rs. 391 per share on December 19, 2024, to anchor investors.
Ahmedabad-based Senores Pharmaceuticals has garnered Rs 260.62 crores from anchor investors ahead of its initial public offering that opened for public subscription on December 20, 2024. The company informed the bourses that it allocated 66,65,725 equity shares at Rs. 391 per share on December 19, 2024, to anchor investors.
Foreign and Domestic Institutions who participated in the anchor included ICICI Prudential Mutual Fund, Aditya Birla Sun Life Insurance, Mahindra ManuLife Large & Mid Cap Fund, Bank of India Multicap Fund, Bank of India Mid & Small Cap Equity & Debt Fund, Ikigai Emerging Equity Fund, SBI General Insurance Company, Troo Capital Fund, Meru Investment Fund PCC- Cell I, Edelweiss Life Insurance Company, Astorne Capital VCC – Arven, Beacon Stone Capital VCC – Beacon Stone I, Goldman Sachs Investment (Mauritius), Ashika Global Securities, Integrated Core Strategies Asia, Societe Generale – ODI, Unity Small Finance Bank, Fortune Hands Growth Fund, and Gagandeep Credit Capital.
Out of the total allocation of 66,65,725 equity shares to the anchor investors, 22,99,380 equity shares were allocated to three domestic mutual funds through 4 schemes, i.e. 34.50% of the Total Anchor Book Size.
Equirus Capital, Ambit and Nuvama Wealth Management Limited are the book-running lead managers and Link Intime India is the registrar of the issue.
The IPO is a mix of fresh issues of up to Rs 500 crore and an offer of sale of up to 21,00,00 equity shares by Promoters and Other Selling Shareholders.
